April 20, 2016 | Bluebird bio has released interim data from its Phase 2/3 trial of its gene therapy Lenti-D, which suggests the approach may be comparably effective to bone marrow transplant for children with the rare disease cerebral adrenoleukodystrophy. TheStreet